A detailed history of Pdt Partners, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 14,814 shares of NTLA stock, worth $211,840. This represents 0.03% of its overall portfolio holdings.

Number of Shares
14,814
Previous 227,220 93.48%
Holding current value
$211,840
Previous $5.09 Million 94.02%
% of portfolio
0.03%
Previous 0.52%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $4.19 Million - $5.81 Million
-212,406 Reduced 93.48%
14,814 $304,000
Q2 2024

Aug 15, 2024

BUY
$20.02 - $27.22 $85,064 - $115,657
4,249 Added 1.91%
227,220 $5.09 Million
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $1.48 Million - $2.03 Million
61,974 Added 38.49%
222,971 $6.13 Million
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $2.87 Million - $4.01 Million
123,920 Added 334.22%
160,997 $4.91 Million
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $1.17 Million - $1.7 Million
37,077 New
37,077 $1.17 Million
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $2.45 Million - $3.36 Million
-24,300 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $3.56 Million - $4.76 Million
-26,900 Reduced 52.54%
24,300 $3.26 Million
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $166,628 - $443,147
-2,737 Reduced 5.07%
51,200 $8.29 Million
Q1 2021

May 17, 2021

SELL
$46.59 - $83.68 $1.7 Million - $3.05 Million
-36,463 Reduced 40.34%
53,937 $4.33 Million
Q4 2020

Feb 16, 2021

BUY
$18.83 - $63.53 $129,757 - $437,785
6,891 Added 8.25%
90,400 $4.92 Million
Q3 2020

Nov 16, 2020

SELL
$17.47 - $24.93 $325,535 - $464,545
-18,634 Reduced 18.24%
83,509 $1.66 Million
Q2 2020

Aug 14, 2020

SELL
$11.14 - $22.87 $10,660 - $21,886
-957 Reduced 0.93%
102,143 $2.15 Million
Q1 2020

May 15, 2020

BUY
$9.44 - $15.58 $165,983 - $273,943
17,583 Added 20.56%
103,100 $1.26 Million
Q4 2019

Feb 14, 2020

BUY
$10.43 - $17.67 $284,916 - $482,691
27,317 Added 46.94%
85,517 $1.26 Million
Q3 2019

Nov 14, 2019

SELL
$13.07 - $18.51 $1,150 - $1,628
-88 Reduced 0.15%
58,200 $777,000
Q2 2019

Aug 14, 2019

BUY
$13.88 - $18.41 $809,037 - $1.07 Million
58,288 New
58,288 $954,000
Q1 2019

May 15, 2019

SELL
$12.79 - $17.62 $1.12 Million - $1.55 Million
-87,743 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$11.39 - $27.13 $193 - $461
17 Added 0.02%
87,743 $1.2 Million
Q3 2018

Nov 14, 2018

SELL
$25.78 - $32.6 $484,225 - $612,325
-18,783 Reduced 17.64%
87,726 $2.51 Million
Q2 2018

Aug 14, 2018

SELL
$20.02 - $30.79 $175,074 - $269,258
-8,745 Reduced 7.59%
106,509 $2.91 Million
Q1 2018

May 15, 2018

BUY
$19.43 - $34.95 $2.24 Million - $4.03 Million
115,254 New
115,254 $2.43 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.